Lipid Disorders and Metabolic-Associated Fatty Liver Disease

Area of Science:

• Hepatology
• Metabolic Syndrome
• Lipidology

Background:

• Dyslipidemia is a known risk factor for metabolic-associated fatty liver disease (MAFLD).
• Genetic and transcriptional factors influencing lipid metabolism contribute to MAFLD susceptibility.
• Hepatic steatosis, NASH, and MAFLD development involve multiple parallel pathways.

Purpose of the Study:

• To explore the intricate relationship between dyslipidemia and MAFLD.
• To elucidate the molecular mechanisms underlying MAFLD pathogenesis.
• To outline current management strategies for MAFLD-associated dyslipidemia.

Main Methods:

• Review of existing literature on lipid metabolism, MAFLD, and cardiovascular risk.
• Analysis of proposed pathogenetic mechanisms including insulin resistance, lipogenesis, and mitochondrial dysfunction.
• Synthesis of evidence regarding therapeutic interventions.

Main Results:

• Insulin resistance, excess free fatty acids, and de novo lipogenesis contribute to hepatic fat accumulation.
• Impaired mitochondrial beta-oxidation and VLDL export exacerbate MAFLD.
• Dyslipidemia in MAFLD significantly increases cardiovascular risk.

Conclusions:

• MAFLD pathogenesis is multifactorial, involving complex lipid metabolism disturbances.
• Effective management of MAFLD-associated dyslipidemia requires a multi-pronged approach.
• Lifestyle modifications and pharmacotherapy are crucial for mitigating MAFLD progression and cardiovascular complications.